News headlines about West Pharmaceutical Services (NYSE:WST) have been trending positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. West Pharmaceutical Services earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 45.9261052389967 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of West Pharmaceutical Services (WST) opened at 95.21 on Monday. West Pharmaceutical Services has a 1-year low of $70.17 and a 1-year high of $99.91. The company has a market capitalization of $7.05 billion, a PE ratio of 40.86 and a beta of 1.13. The firm has a 50-day moving average price of $87.78 and a 200-day moving average price of $89.57.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The business had revenue of $397.60 million for the quarter, compared to analyst estimates of $406.00 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. West Pharmaceutical Services’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.59 EPS. Equities analysts anticipate that West Pharmaceutical Services will post $2.68 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Wednesday, October 18th will be paid a $0.14 dividend. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend is Tuesday, October 17th. This represents a $0.56 annualized dividend and a yield of 0.59%. West Pharmaceutical Services’s payout ratio is currently 22.22%.

WST has been the topic of a number of recent research reports. Jefferies Group LLC upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and raised their target price for the company from $96.00 to $115.00 in a research note on Friday, September 15th. BidaskClub cut West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Finally, Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research note on Saturday, June 17th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $98.52.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Insider Buying and Selling by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with's FREE daily email newsletter.